Short answer
Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Senior VP Development and Head of Ireland Office Áine Miller departing November 15, 2026 amid restructuring.
Theravance Biopharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Senior VP Development and Head of Ireland Office Áine Miller departing November 15, 2026 amid restructuring
- $250,000 special pension contribution due within 30 days after termination
- 18,750 restricted share units granted for continued service through termination date
- Departure creates leadership transition risk across development and Ireland operations
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Theravance Biopharma, Inc. 8-K filings
Get the next TBPH 8-K as it lands
Follow TBPH for push alerts, or ask the research agent what this filing means.